Dr. Frances Shepherd CV - (NCRI) is

29. Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, et al, Shepherd FA,
Christiani DC, Liu G. A rapid outcomes ascertainment system improves the quality of
prognostic and pharmacogenic outcomes fromobservational studies. Cancer Epidemiol
Biomarkers Prev.: 17(1): 204-11. Jan 2008.
30. Fruh M, Zhou W, Zhai R, Su L, Heist RS, Lynch, TJ, Shepherd FA, Christiani DL, Liu
G. Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori
infection and the risk of eosophageal adenocarcinoma. Cancer Epidermal 2008; 98: 689-
92.
31. Wakelee H, Langer C,Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Shepherd FA, Choy
H, Gandara DR. Cooperative group research efforts in lung cancer: focus on early-stage
non-small cell lung cancer. Clin Lung Cancer 9: 9-15, 2008.
32. Wheatley-Price P, Shepherd FA. Epidermal growth factor receptor inhibitors in the
treatment of lung cancer: reality and hopes. Curr Opin Oncol. 2: 162-75, 2008.
33. Gridelli C, Ardizzoni A. Ciardiello F, Shepherd FA, et al. Second-line treatment of
advanced non-small cell lung cancer. J Thorac Onc 3: 430-40, 2008
34. Laurie SA, Gouthier I, Arnold A, Shepherd FA, et al Seymour L. Phase I and
pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial
growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients
with advanced non-small-cell lung cancer: the National Cancer Institute of Canada
clinical trials group. J Clin Oncol. 26: 1871-8, 2008
35. Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd FA, Vokes EE, Adjei AA, Baas P,
Saijo N, Gandara DR. Cooperative group portfolio in locally advanced non-small cell
lung cancer: are we making progress? Clin Lung Cancer; 9 (2): 85-91 Mar 2008.
36. Lee CW, Martin J, MacRae R, Tsao MS, Nguyen E, Johnston M, Baas P, Laurie S, Feld
R, Murrya N, Shepherd FA. Malignant mesothelioma: Canadian perspective and
research directions. Current Oncology 152: 104 – 111, 2008.
37. Wheatley-Price P, Ding K, Seymopur L, Clark GM, Shepherd FA. Erlotinib for
advanced non-small cell lung cancer in the elderly: an analysis of the National Cancer
Institute of Canada Clinical Trials Grooup Study BR.21. J Clin Oncol. 26(14): 1250-7.
May 2008.
38. Shepherd FA. Molecular selection of patients for first-line treatment of advanced nonsmall
cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime
time. J. Clin Oncol. 20: (15): 2426-7 May 2008.
39. Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of
EGFR mutation in lung adenocarcinoma. J Thorac Oncol: 3 (5): 527-9. 2008.
40. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, et al., Chevalier T.
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative
Group. J Clin. Oncol. 2008; 26: 2552-9.
41. Leighl NB, Shepherd FA, Zawisca D, Burkes RL, Feld R, Waldron J, Sun A, Payne D,
Bezjak A. Enhancing treatment decision-making: pilot study of a treatment decision aid
in stage IV non-small cell lung cancer. Br J Cancer. 98(11): 1769-73. May 2008.
42. Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA. A clinical prognostic index for
patients treated with erlotinib in National Cancer Institute of Canada Clinical Trial Group
study BR.21. J Thorac Oncol. 3(6): 590-8. Jun 2008.
43. Lynch TJ, Blumenschein GR Jr, Engelman JA, et al. Shepherd FA, Socinski M,
Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the
treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for
combination therapy. J Thorac Oncol. 3 (6 suppl 2): S107-12. Hun 2008.
44. Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. J Thorac Oncol. 3 (6 suppl
2): S164-70.
8